Inclusion Criteria:

          -  Have histologically proven pancreatic cancer that is borderline resectable

          -  No more than 1 month/cycle (28 days) of systemic therapy for pancreatic cancer

          -  Age >18 years old.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests.

          -  Woman of child bearing potential must have a negative pregnancy test.

          -  Must use an acceptable form of birth control while on study.

          -  Must be candidate for Stereotactic Body Radiation Therapy (SBRT)

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Had major surgery within the last 28 days

          -  Had an investigational drug or device within the past 28 days

          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CTLA4, etc)

          -  Completed more than 1 month/cycle (28 days) of chemotherapy for pancreas cancer

          -  Patient on an immunosuppressive systemic treatment, such as steroids, in the past 2
             years.

          -  Other cancer diagnosis requiring treatment within two years

          -  History of allergic reactions related to the drugs (Nivolumab, Cyclophosphamide,
             GM-hetastarch, corn, dimethyl sulfoxide, fetal bovine serum, trypsin (porcine origin),
             yeast or any other component of the GVAX vaccine) in this study.

          -  Patients receiving growth factors within the last 14 days.

          -  Currently have or have history of certain study-specified heart, liver, kidney, lung,
             neurological, psychological, immune or other medical conditions.

          -  Pregnant or breastfeeding.

          -  Have known history of infection with HIV, hepatitis B, or hepatitis C.

          -  Unwilling or unable to follow the study schedule for any reason.

          -  Presence of tissue or organ allograft, regardless of need for immunosuppression
             (including corneal allograft)

          -  Squamous pancreatic cancer or adenosquamous pancreatic cancer with malignant squamous
             cells >30%